View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 7, 2020

Assertio to divest US rights to Nucynta to Collegium for $375m

Assertio Therapeutics has signed a definitive agreement to sell its Nucynta franchise to Collegium Pharmaceutical for a cash consideration of $375m.

Assertio Therapeutics has signed a definitive agreement to sell its Nucynta franchise to Collegium Pharmaceutical for a cash consideration of $375m.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

The deal will provide Collegium with the US licence for the Nucynta franchise of products. Besides $375m, Collegium will pay Assertio for some inventories and equipment related to the products.

Under the agreement, Collegium will be exempt from paying royalties to Assertio.

However, the company will continue to pay 14% sales royalty on the Nucynta franchise to Grunenthal but will not be required to pay additional royalty on sales higher than $180m.

Nucynta is made up of an opioid to manage acute pain in adults who experience inadequate response or are intolerant to other pain medication such as non-opioid pain drugs.

The Nucynta franchise comprises extended-release and an immediate-release formulation of tapentadol. Patents for the products expire in June 2025. Collegium notes that the franchise may receive a six-month paediatric extension.

Assertio Therapeutics president and CEO Arthur Higgins said: “With this transaction, our goal is to retire our outstanding debt and have approximately $50m of cash on our balance sheet.

“We will use this new flexibility to pursue business development, strategic partnerships and investment opportunities with the goal of having our remaining business becoming cash flow and EBITDA positive by the end of the year.”

Stifel was the financial advisor to Assertio, while Gibson, Dunn & Crutcher and Greenberg Traurig acted as legal counsel.

Collegium Pharmaceutical president and CEO Joe Ciaffoni said: “Acquiring the full US rights to the Nucynta franchise is financially transformative for Collegium. We expect the acquisition to improve annual EBITDA and operating cash flows by more than $100m.

“The transaction is supported by a financing structure that allows for rapid de-leveraging and enables us to pursue future business development transactions.”

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology